SCHEMBL860342

SCHEMBL860342

CC(NC(=O)CC(=O)Nc1ccc(C(=N)N)cc1)c1ccc(OC2CCN(C3CC3)C2)c(C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
F2 P00734 13/20 0.50
F7 P08709 12/20 0.50
F10 P00742 8/20 0.48
ACACB O00763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL860902 0.92 F2 (0.52) F2F7F10ACACB
SCHEMBL860960 0.88 F7 (0.48) F2F7F10
SCHEMBL860972 0.87 F2 (0.49) F2F7F10
SCHEMBL860322 0.86 F2 (0.56) F2F7F10
SCHEMBL860387 0.86 F2 (0.53) F2F7F10
SCHEMBL842070 0.85 F2 (0.48) F2F7F10
SCHEMBL860380 0.83 F7 (0.49) F2F7F10
SCHEMBL860691 0.83 F2 (0.47) F2F7F10
SCHEMBL860343 0.83 F7 (0.48) F2F7F10
Trifluoroacetic Acid SCHEMBL841558 0.81 F7 (0.45) F2F7F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143242-B2 Malonamide derivatives with antithrombotic activity SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
US-8143242-B2 Malonamide derivatives with antithrombotic activity SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2010-09-30 US disclosed
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY F7, F9, TFPI F2 23/4885F7 1/4885F10 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.